Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
29 November 2022

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors

Authors: Prina Donga, Bruno Emond, Aditi Shah, Brahim K Bookhart, David Anderson, Maude Vermette-Laforme, Carmine Rossi [email protected], and Marie-Hélène LafeuilleAuthor Info & Affiliations
Volume 12, Number 1
https://doi.org/10.2217/cer-2022-0147
PDFFormats

Abstract

Aim: Compare weight changes between people living with HIV-1 (PLWH) at high risk of weight gain (females, Blacks or Hispanics) switching from an integrase strand transfer inhibitor (INSTI) to a protease inhibitor (PI) or another INSTI. Materials & methods: Mean weight changes from pre-switch to up-to-12 months post-switch were retrospectively compared between PLWH switching to a PI or INSTI. Results: 356 PLWH were eligible. At 9- and 12-month post-switch, weight increases were observed for INSTI (weight: +1.55 kg and +1.59 kg), while decreases were observed for PI (-0.23 kg and -1.59 kg); differences between cohorts widened over time. Conclusion: These data suggest that switching off an INSTI may be a management tool to mitigate or reverse weight gain.

Tweetable abstract

ART management may be an option to mitigate or reverse weight gain following initial INSTI treatment among female, Black or Hispanic PLWH who have a higher risk of weight gain.

Supplementary Material

File (supplementary figure.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Arasteh K, Yeni P, Pozniak A et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 14(6), 859–864 (2009).
PubMed
Google Scholar
2.
Farnham PG, Gopalappa C, Sansom SL et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J. Acquir. Immune Defic. Syndr. 64(2), 183–189 (2013).
PubMed
Google Scholar
3.
Lundgren JD, Babiker AG, Gordin F et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373(9), 795–807 (2015).
PubMed
Google Scholar
4.
Lifson AR, Grund B, Gardner EM et al. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS 31(7), 953–963 (2017).
PubMed
Google Scholar
5.
Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection – a trend analysis. J. Infect. Dis. 216(12), 1525–1533 (2017).
PubMed
Google Scholar
• A large cohort study (>64,000 PLWH) which matched PLWH to HIV-negative controls in the US between 2003 and 2013. The reported findings include an increased comorbidity burden among PLWH, with the most common comorbidities being essential hypertension, hyperlipidemia and endocrine disorders.
6.
Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 30(6), 1562–1566 (2007).
PubMed
Google Scholar
7.
Bae YS, Choi S, Lee K et al. Association of concurrent changes in metabolic health and weight on cardiovascular disease risk: a nationally representative cohort study. J. Am. Heart Assoc. 8(17), e011825 (2019).
PubMed
Google Scholar
8.
Koethe JR, Jenkins CA, Lau B et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res. Hum. Retroviruses 32(1), 50–58 (2016).
PubMed
Google Scholar
• A large cohort study (>14,000 PLWH) which matched PLWH to HIV-negative controls in North America between 1998 and 2010. The reported findings include an increase in baseline BMI from 23.8 to 24.8 kg/m2 when initiating ART, as well as an increase in the proportion of PLWH who were obese when initiating ART; 18% of normal BMI PLWH became obese after 3 years of ART.
9.
Silverberg M, Leyden W, Alexeef S et al. Changes in body mass index over time in persons with and without HIV. 23rd International AIDS Conference (2020).
Google Scholar
10.
Buzón-Martín L. Weight gain in HIV-infected individuals using distinct antiretroviral drugs. AIDS Rev. 22(3), 158–167 (2020).
PubMed
Google Scholar
11.
Mazzitelli M, Isabel Pereira B, Moyle G et al. Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age. AIDS Care 34(4), 542–544 (2022).
PubMed
Google Scholar
12.
Asundi A, Olson A, Jiang W et al. Integrase inhibitor use associated with weight gain in women and incident diabetes mellitus. AIDS Res. Hum. Retroviruses 38(3), 208–215 (2022).
PubMed
Google Scholar
13.
Bedimo R, Adams-Huet B, Taylor B, Lake J, Luque A. 538. Integrase inhibitor-based HAART is associated with greater BMI gains in Blacks, Hispanics, and women. Open Forum Infect. Dis. 5(S1), S199 (2018).
Google Scholar
14.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (updated September 21, 2022). https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (October 5, 2022).
Google Scholar
15.
Eckard AR, Mccomsey GA. Weight gain and integrase inhibitors. Curr. Opin. Infect. Dis. 33(1), 10–19 (2020).
PubMed
Google Scholar
16.
Chow W, Donga P, Côté-Sergent A et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr. Med. Res. Opin. 36(8), 1313–1323 (2020).
PubMed
Google Scholar
•• A large, recent cohort study (>20,000 PLWH) which generated balanced cohorts (using IPTW) of PLWH initiating an INSTI or a PI in the US between 2017 and 2019. The PI cohort was significantly less likely to experience ≥5% weight or BMI gain (OR [≥5% weight gain] = 0.61; p = .014; OR [≥5% BMI gain] = 0.51; p < .001), and mean weight/BMI gain was significantly lower in the PI cohort.
17.
Emond B, Rossi C, Cote-Sergent A et al. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr. Med. Res. Opin. 38(2), 287–298 (2022).
PubMed
Google Scholar
• Recent cohort study which generated balanced cohorts (>1,000 PLWH per cohort; balanced using IPTW) who were treatment-naïve or virologically suppressed and initiated either single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/c/FTC/TAF) or bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) between 2017 and 2020. Reported results included a larger BMI or weight increase at consecutive time points in PLWH initiating BIC/FTC/TAF (12 months: mean difference in BMI = 1.23 kg/m2; p < .001; mean difference in weight = 2.84 kg [6.26 lbs]; p = 0.008) relative to those initiating DRV/c/FTC/TAF.
18.
Bourgi K, Jenkins CA, Rebeiro PF et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J. Int. AIDS Soc. 23(4), e25484 (2020).
PubMed
Google Scholar
19.
Wu KS, Anderson C, Little SJ. Integrase strand transfer inhibitors play the main role in greater weight gain among men with acute and early HIV infection. Open Forum Infect. Dis. 8(1), ofaa619 (2021).
PubMed
Google Scholar
20.
Norwood J, Turner M, Bofill C et al. Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J. Acquir. Immune. Defic. Syndr. 76(5), 527 (2017).
PubMed
Google Scholar
21.
Pantazis N, Papastamopoulos V, Antoniadou A et al. Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug. Viruses 14(8), (2022).
PubMed
Google Scholar
22.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34(28), 3661–3679 (2015).
PubMed
Google Scholar
23.
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083–3107 (2009).
PubMed
Google Scholar
24.
Bourgi K, Rebeiro PF, Turner M et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin. Infect. Dis. 70(7), 1267–1274 (2020).
PubMed
Google Scholar
25.
Chen YW, Hardy H, Pericone CD, Chow W. Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors. J. Health Econ. Outcomes Res. 7(2), 102–110 (2020).
PubMed
Google Scholar
•• A recent cohort study using electronic health records between 2016 and 2018 with matched US cohorts (>1,500 PLWH), half of whom initiated a PI-based ART regimen and half of whom initiated an INSTI-based regimen. The reported findings include a significantly greater mean weight gain among INSTI initiators (1.3 kg) (95% CI: 0.5–2.0), a higher proportion with ≥5% weight gain (OR = 1.3, 95% CI: 1.0–1.6), and a 2.5 kg greater mean weight gain (95% CI: 0.7–4.2) and a higher proportion with ≥5% weight gain in females, relative to PI initiators.
26.
Mounzer K, Brunet L, Hsu R et al. Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States. AIDS Res. Hum. Retroviruses 37(11), 852–861 (2021).
PubMed
Google Scholar
27.
Mazzitelli M, Trunfio M, Putaggio C et al. Viro-immunological, clinical outcomes and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week prospective analysis. Biomedicines 10(8), 1823 (2022).
PubMed
Google Scholar
28.
Venter WDF, Sokhela S, Calmy A et al. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS 35(Suppl. 2), S183–S188 (2021).
PubMed
Google Scholar
29.
Abbamonte JM, Cristofari NV, Weiss SM, Kumar M, Jayaweera DT, Jones DL. Heart health and behavior change in HIV-infected individuals. AIDS Behav. 25(2), 615–622 (2021).
PubMed
Google Scholar
31.
Lake JE, Wu K, Bares SH et al. Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy. Clin. Infect. Dis. 71(9), e471–e477 (2020).
PubMed
Google Scholar
32.
Sax PE, Erlandson KM, Lake JE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin. Infect. Dis. 71(6), 1379–1389 (2020).
PubMed
Google Scholar
33.
Coelho LE, Jenkins CA, Shepherd BE et al. Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America. The Lancet Regional Health – Americas 8 (2022).
Google Scholar
34.
Chen Y-W, Anderson D, Pericone CD, Donga P. Real-world assessment of weight change in African American females and Hispanics with HIV-1 after initiating integrase strand-transfer inhibitors or protease inhibitors. J. Health Econ. Outcomes Res. 9(1), 1–10 (2022).
PubMed
Google Scholar
•• A recent study which included two cohorts of female African Americans (>3400 PLWH) or Hispanics (>1800 PLWH) who initiated either a PI-based ART regimen or an INSTI-based ART regimen between 2015 and 2018, balanced via IPTW. Main findings include female African American INSTI initiators having 1.5 kg greater mean weight gain (2.1 kg vs 0.6 kg; p = 0.033), and a higher proportion with ≥5% weight gain (odds ratio [OR] = 1.2; 95% CI [1.0–1.4]) compared to PI initiators; among Hispanics, INSTI initiators had a higher proportion with ≥5% weight gain.
35.
Nduka CU, Stranges S, Kimani PK, Sarki AM, Uthman OA. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab. Res. Rev. 33(6), (2017).
PubMed
Google Scholar
36.
Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front. Endocrinol. (Lausanne) 9, 705 (2018).
PubMed
Google Scholar
37.
Herrin M, Tate JP, Akgun KM et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J. Acquir. Immune Defic. Syndr. 73(2), 228–236 (2016).
PubMed
Google Scholar
38.
Mccann K, Shah S, Hindley L et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS 35(10), 1657–1665 (2021).
PubMed
Google Scholar
39.
Mccomsey GA, Emond B, Shah A et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with HIV-1 at high risk of weight gain initiated on antiretroviral therapy. Infect. Dis. Ther. (2022) (Epub ahead of print).
Crossref
PubMed
Google Scholar
40.
Petoumenos K, Kuwanda L, Ryom L et al. Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in hiv-positive individuals: results from the D:A:D Study. J. Acquir. Immune Defic. Syndr. 86(5), 579–586 (2021).
PubMed
Google Scholar
41.
A study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) evaluated as a fixed dose combination regimen in participants switching from an integrase inhibitor who have experienced rapid weight gain (DEFINE). https://clinicaltrials.gov/ct2/show/NCT04442737 (2022).
Google Scholar
42.
Doravirine for persons with excessive weight gain on integrase inhibitors and tenofovir alafenamide. https://clinicaltrials.gov/ct2/show/NCT04636437 (2022).
Google Scholar
43.
Venter WDF, Moorhouse M, Sokhela S et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N. Engl. J. Med. 381(9), 803–815 (2019).
PubMed
Google Scholar
44.
Mallon PW, Brunet L, Hsu RK et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J. Int. AIDS Soc. 24(4), e25702–e25702 (2021).
PubMed
Google Scholar
|